Huntsman vs Chemours: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Huntsman Corporation (HUN)

Q3 202617 Jun – 4 Aug 2026

▲2▼2

Huntsman's merger with Olin and price hikes offset by weak demand and overcapacity

Merger with Olin to create $12.5B chemicals leader Huntsman and Olin agreed to an all-stock merger, forming OlinHuntsman with $12.5B in revenue. The deal promises over $400M in cost savings, which could add $8-11 per share in value. This is a major strategic move that could boost HUN's long-term earnings power.
The merger is the biggest recent event and directly affects HUN's future value.
Huntsman shares plunge 17% on discounted merger valuation Despite the merger's potential, Huntsman shares fell 17% because the all-stock deal valued HUN at a discount. This reflects investor concerns about the immediate value received and the risk that the combined company may face integration challenges.
The sharp negative market reaction shows how investors initially viewed the deal terms.
Huntsman raises MDI prices amid industry-wide hikes Huntsman increased MDI prices in Europe, Africa, the Middle East, and India, following similar moves by peers. The hikes are driven by higher raw material and logistics costs and tight supply from plant maintenance. This could improve Huntsman's margins and profitability.
Price hikes directly impact Huntsman's revenue and earnings, a key driver of the stock.
Q2 earnings beat but stock falls 19% on overcapacity fears Huntsman reported higher Q2 sales and a narrower loss, yet shares dropped 19% in a day. Investors are worried about industry overcapacity and weak construction demand, which could keep prices and volumes under pressure despite the recent price hikes.
The market's negative reaction to earnings highlights persistent concerns that overshadow positive results.

July 202617 Jun – 4 Aug 2026

▲2▼2

Huntsman's merger with Olin and price hikes offset by weak demand and overcapacity

Merger with Olin to create $12.5B chemicals leader Huntsman and Olin agreed to an all-stock merger, forming OlinHuntsman with $12.5B in revenue. The deal promises over $400M in cost savings, which could add $8-11 per share in value. This is a major strategic move that could boost HUN's long-term earnings power.
The merger is the biggest recent event and directly affects HUN's future value.
Huntsman shares plunge 17% on discounted merger valuation Despite the merger's potential, Huntsman shares fell 17% because the all-stock deal valued HUN at a discount. This reflects investor concerns about the immediate value received and the risk that the combined company may face integration challenges.
The sharp negative market reaction shows how investors initially viewed the deal terms.
Huntsman raises MDI prices amid industry-wide hikes Huntsman increased MDI prices in Europe, Africa, the Middle East, and India, following similar moves by peers. The hikes are driven by higher raw material and logistics costs and tight supply from plant maintenance. This could improve Huntsman's margins and profitability.
Price hikes directly impact Huntsman's revenue and earnings, a key driver of the stock.
Q2 earnings beat but stock falls 19% on overcapacity fears Huntsman reported higher Q2 sales and a narrower loss, yet shares dropped 19% in a day. Investors are worried about industry overcapacity and weak construction demand, which could keep prices and volumes under pressure despite the recent price hikes.
The market's negative reaction to earnings highlights persistent concerns that overshadow positive results.

Latest17 Jun – 4 Aug 2026

▲2▼2

Huntsman's merger with Olin and price hikes offset by weak demand and overcapacity

Merger with Olin to create $12.5B chemicals leader Huntsman and Olin agreed to an all-stock merger, forming OlinHuntsman with $12.5B in revenue. The deal promises over $400M in cost savings, which could add $8-11 per share in value. This is a major strategic move that could boost HUN's long-term earnings power.
The merger is the biggest recent event and directly affects HUN's future value.
Huntsman shares plunge 17% on discounted merger valuation Despite the merger's potential, Huntsman shares fell 17% because the all-stock deal valued HUN at a discount. This reflects investor concerns about the immediate value received and the risk that the combined company may face integration challenges.
The sharp negative market reaction shows how investors initially viewed the deal terms.
Huntsman raises MDI prices amid industry-wide hikes Huntsman increased MDI prices in Europe, Africa, the Middle East, and India, following similar moves by peers. The hikes are driven by higher raw material and logistics costs and tight supply from plant maintenance. This could improve Huntsman's margins and profitability.
Price hikes directly impact Huntsman's revenue and earnings, a key driver of the stock.
Q2 earnings beat but stock falls 19% on overcapacity fears Huntsman reported higher Q2 sales and a narrower loss, yet shares dropped 19% in a day. Investors are worried about industry overcapacity and weak construction demand, which could keep prices and volumes under pressure despite the recent price hikes.
The market's negative reaction to earnings highlights persistent concerns that overshadow positive results.

Chemours Co (CC)

Q3 202624 Jun – 7 Aug 2026

▲2▼2

Chemours settles PFAS suits, sets 2026 guidance; new state lawsuits add risk

EPA PFAS settlement removes major regulatory overhang Chemours agreed to pay a $22.5 million penalty and fund $90 million in PFAS mitigation projects, resolving a major federal dispute. The stock jumped 6.1% on the news as investors saw the settlement as a known cost that clears a big legal cloud, making future cash flows more predictable.
This is the period's biggest positive catalyst, directly lifting CC shares by reducing uncertainty.
New York and other states sue over PFAS contamination New York State sued 3M, DuPont, and Chemours spinoffs over PFAS, seeking cleanup costs and penalties. This adds fresh legal risk and potential future payouts, which can weigh on CC's stock because investors worry about unknown liabilities and cash outflows.
It introduces a new legal threat that could increase costs and uncertainty for CC.
2026 guidance shows earnings growth and deleveraging Chemours guided 2026 adjusted EBITDA to $775–$825 million and net leverage to about 3.8x, with Q2 beating expectations on pricing strength and cost cuts. This signals improving profits and a stronger balance sheet, supporting a higher stock price as investors gain confidence in the business.
It provides a forward-looking financial picture that directly influences CC's valuation.
Court approves $2.5 billion New Jersey PFAS settlements A federal judge approved over $2.5 billion in PFAS settlements involving DuPont, 3M, Chemours, and Corteva. While this resolves some claims, it confirms large legacy costs for Chemours, which can pressure the stock as investors factor in the cash outflows.
It finalizes a major liability that affects CC's financial obligations and investor sentiment.

July 202624 Jun – 7 Aug 2026

▲2▼2

Chemours settles PFAS suits, sets 2026 guidance; new state lawsuits add risk

EPA PFAS settlement removes major regulatory overhang Chemours agreed to pay a $22.5 million penalty and fund $90 million in PFAS mitigation projects, resolving a major federal dispute. The stock jumped 6.1% on the news as investors saw the settlement as a known cost that clears a big legal cloud, making future cash flows more predictable.
This is the period's biggest positive catalyst, directly lifting CC shares by reducing uncertainty.
New York and other states sue over PFAS contamination New York State sued 3M, DuPont, and Chemours spinoffs over PFAS, seeking cleanup costs and penalties. This adds fresh legal risk and potential future payouts, which can weigh on CC's stock because investors worry about unknown liabilities and cash outflows.
It introduces a new legal threat that could increase costs and uncertainty for CC.
2026 guidance shows earnings growth and deleveraging Chemours guided 2026 adjusted EBITDA to $775–$825 million and net leverage to about 3.8x, with Q2 beating expectations on pricing strength and cost cuts. This signals improving profits and a stronger balance sheet, supporting a higher stock price as investors gain confidence in the business.
It provides a forward-looking financial picture that directly influences CC's valuation.
Court approves $2.5 billion New Jersey PFAS settlements A federal judge approved over $2.5 billion in PFAS settlements involving DuPont, 3M, Chemours, and Corteva. While this resolves some claims, it confirms large legacy costs for Chemours, which can pressure the stock as investors factor in the cash outflows.
It finalizes a major liability that affects CC's financial obligations and investor sentiment.

Latest24 Jun – 7 Aug 2026

▲2▼2

Chemours settles PFAS suits, sets 2026 guidance; new state lawsuits add risk

EPA PFAS settlement removes major regulatory overhang Chemours agreed to pay a $22.5 million penalty and fund $90 million in PFAS mitigation projects, resolving a major federal dispute. The stock jumped 6.1% on the news as investors saw the settlement as a known cost that clears a big legal cloud, making future cash flows more predictable.
This is the period's biggest positive catalyst, directly lifting CC shares by reducing uncertainty.
New York and other states sue over PFAS contamination New York State sued 3M, DuPont, and Chemours spinoffs over PFAS, seeking cleanup costs and penalties. This adds fresh legal risk and potential future payouts, which can weigh on CC's stock because investors worry about unknown liabilities and cash outflows.
It introduces a new legal threat that could increase costs and uncertainty for CC.
2026 guidance shows earnings growth and deleveraging Chemours guided 2026 adjusted EBITDA to $775–$825 million and net leverage to about 3.8x, with Q2 beating expectations on pricing strength and cost cuts. This signals improving profits and a stronger balance sheet, supporting a higher stock price as investors gain confidence in the business.
It provides a forward-looking financial picture that directly influences CC's valuation.
Court approves $2.5 billion New Jersey PFAS settlements A federal judge approved over $2.5 billion in PFAS settlements involving DuPont, 3M, Chemours, and Corteva. While this resolves some claims, it confirms large legacy costs for Chemours, which can pressure the stock as investors factor in the cash outflows.
It finalizes a major liability that affects CC's financial obligations and investor sentiment.